Status | Study |
Not yet recruiting |
Study Name: Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial Condition: Dyspnea Date: 2017-05-10 Interventions: Drug: Sirolimus mTOR inhibitor or placebo Other Name |
Not yet recruiting |
Study Name: LAM Pilot Study With Imatinib Mesylate Condition: Lymphangioleiomyomatosis Date: 2017-04-24 Interventions: Drug: Imatinib Mesylate 400Mg Capsule |
Recruiting |
Study Name: A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) Condition: Lymphangioleiomyomatosis Date: 2016-10-07 Interventions: Drug: Nintedanib Other Name: OFEV |
Recruiting |
Study Name: The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients Condition: Interstitial Pulmonary Fibrosis ARDS COPD (Chronic Obstructive Pulmonary Disease) Date: 2016-07-21 Interventions: Procedure: Veno-veno-arterial ECMO |
Recruiting |
Study Name: Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis Condition: Pulmonary Lymphangioleiomyomatosis Date: 2016-03-31 Interventions: Drug: saracatinib Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject wi |
Recruiting |
Study Name: COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC Condition: Lymphangioleiomyomatosis (LAM) Date: 2015-06-25 Interventions: Drug: Celecoxib We will perform a pilot clinical trial to investigate the safety and tolerability of cel |
Recruiting |
Study Name: Lymphatic Anomalies Registry Condition: Lymphatic Malformation Generalized Lymphatic Anomaly (GLA) Date: 2015-03-17 |
Recruiting |
Study Name: Safety and Durability of Sirolimus for Treatment of LAM Condition: Lymphangioleiomyomatosis Date: 2015-03-04 Interventions: Drug: Sirolimus Sirolimus trea |
Recruiting |
Study Name: Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Condition: Tuberous Sclerosis Lymphangioleiomyomatosis Angiomyolipoma Date: 2014-12-14 |
Completed |
Study Name: The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) Condition: Pulmonary Lymphangioleiomyomatosis Date: 2014-04-15 Interventions: Drug: Saracatinib Saracatinib is escalated as follows: Three dose levels will be administered for 1 mont |